The new strategy sets out UKHSA’s vision and goals for the next 3 years to prepare for and respond to health threats and build the capabilities and technologies to protect the country in the future.
Atezolizumab by F. Hoffmann-La Roche for Glioblastoma Multiforme (GBM): Likelihood of Approval
Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug